Literature DB >> 9119100

Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.

A Z Isik1, O Gokmen, H B Zeyneloglu, S Kara, G Keles, B Gulekli.   

Abstract

OBJECTIVE: To assess the effectiveness of intravenous administration of albumin in prevention of ovarian hyperstimulation syndrome (OHSS) in patients of an in-vitro fertilization program. STUDY
DESIGN: Prospective randomized study. Patients with hCG day E2 levels are 11010 pmol/l (3000 pg/ml) or more were recruited into two groups. Group A (n = 27) received 10 g 20%, 50 ml human albumin infusion before oocyte pick-up and no medication was administered in Group B (n = 28).
RESULTS: Patients were similar in terms of cycle characteristics. No moderate-severe OHSS developed in Group A whereas one severe OHSS case and four moderate OHSS cases developed in Group B. Statistical analysis revealed a significant (P < 0.05) protection in albumin treated group.
CONCLUSION: Human albumin proves effectiveness in prevention of moderate-severe OHSS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9119100     DOI: 10.1016/s0301-2115(95)02603-7

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  6 in total

1.  Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.

Authors:  Stephen R Lincoln; Michael S Opsahl; Keith L Blauer; Susan H Black; Joseph D Schulman
Journal:  J Assist Reprod Genet       Date:  2002-04       Impact factor: 3.412

2.  Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.

Authors:  Ensieh Shahrokh Tehraninejad; Maryam Hafezi; Arezoo Arabipoor; Elham Aziminekoo; Mohammad Chehrazi; Akram Bahmanabadi
Journal:  J Assist Reprod Genet       Date:  2012-01-10       Impact factor: 3.412

Review 3.  Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis.

Authors:  Jun-Liang Guo; Duo-Duo Zhang; Yue Zhao; Dan Zhang; Xi-Meng Zhang; Can-Quan Zhou; Shu-Zhong Yao
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

4.  Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction.

Authors:  Ataollah Ghahiri; Neda Mogharehabed; Minoo Movahedi; Naeimehossadat Hosseini
Journal:  J Res Med Sci       Date:  2015-07       Impact factor: 1.852

5.  Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Di Wu; Hao Shi; Yiping Yu; Ting Yu; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

Review 6.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.